Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.

Autor:	Demiray AG; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Demiray A; Department of Medical Genetics, Pamukkale University Faculty of Medicine, Denizli, Turkey., Yaren A; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Yapar Taşköylü B; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Gököz Doğu G; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Değirmencioğlu S; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Çakıroğlu U; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Özhan N; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Karan C; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Çakan Demirel B; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Doğan T; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey., Özdemir M; Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey.
Jazyk:	angličtina
Zdroj:	The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology [Turk J Gastroenterol] 2022 Aug; Vol. 33 (8), pp. 696-703.
DOI:	10.5152/tjg.2022.21829
Abstrakt:	Background: First-line treatments for metastatic pancreatic cancer are chemotherapy regimens consisting of 5-fluorouracil or gemcitabine; however, there are no biomarkers to help determine which patients might benefit from which treatment regimens. We aimed to show that microRNAs let-7c and 7d can be used as independent predictive biomarkers for metastatic pancreatic cancer. Methods: A total of 55 patients who had first-line chemotherapy with FOLFIRINOX or gemcitabine+capecitabine were included. Patients were divided into groups based on let-7c and let-7d levels and chemotherapy treatment as let-7c-7d high FOLFIRINOX, let7c-7d high gemcitabine+capecitabine, let-7c-7d low FOLFIRINOX, and let-7c-7d low gemcitabine+capecitabine. Blood samples were taken from patients before chemotherapy for microRNA let-7c and 7d analysis. MicroRNA isolation was performed using a miRNeasy Serum/Plasma Kit and identified using spectrophotometric measurements. After isolation, microRNA was converted to cDNA using a microRNA cDNA Synthesis Kit with poly (A) polymerase tailing. The expression of microRNA was examined using quantitative real-time polymerase chain reaction. Results: The overall survival of patients who received FOLFIRINOX treatment with a high let-7c-7d level was statistically significantly longer than those who received gemcitabine+capecitabine with a high let-7c-7d level. In addition, patients with low let-7c expression receiving FOLFIRINOX progressed significantly 2.104 times earlier than patients with high let-7c expression receiving FOLFIRINOX. Conclusion: The serum MicroRNA let-7c level was found to be an independent predictive biomarker in the FOLFIRINOX treatment group.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu